Given that these data show the reduced monocyte inflammatory responses following CERK inhibition or silencing, further studies will be required to validate whether CERK targeting can be useful to alleviate chronic inflammation and insulin resistance in metabolic disorders. This evidence concerns the gene CERK and metabolic disease.